Lipocine Inc
LPCN3.130USD
-0.020-0.63%
Fechamento 08/04, 16:00（ET）Cotações atrasadas em 15 min
16.75MValor de mercado
PerdaP/L TTM
Mais detalhes de Lipocine Inc Empresa
Lipocine Inc. is a biopharmaceutical company leveraging its proprietary technology platform to augment therapeutics through effective oral delivery to develop differentiated products for Central Nervous System (CNS) disorders. Its clinical development candidates include: LPCN 1154, oral brexanolone, for treatment of postpartum depression, LPCN 2101 for epilepsy, LPCN 2203 for essential tremor and LPCN 1148, a novel androgen receptor agonist prodrug for oral administration targeted for the management of symptoms associated with liver cirrhosis. It is exploring partnering opportunities for LPCN 1107, for prevention of preterm birth, LPCN1154, for rapid relief of postpartum depression, LPCN 1148, for the management of decompensated cirrhosis, and LPCN 1144, for treatment of non-cirrhotic NASH. Its product candidate, TLANDO, an oral treatment indicated for testosterone replacement therapy in adult males for conditions associated with a deficiency or absence of endogenous testosterone.
Informações da empresa
Código da empresaLPCN
Nome da EmpresaLipocine Inc
Data de listagemMar 21, 2014
CEODr. Mahesh V. Patel, Ph.D.
Número de funcionários16
Tipo de títulosOrdinary Share
Fim do ano fiscalMar 21
Endereço675 S Arapeen Dr Ste 202
CidadeSALT LAKE CITY
Bolsa de valoresNASDAQ Capital Market Consolidated
PaísUnited States of America
Código postal84108-1295
Telefone18019947383
Sitehttps://www.lipocine.com/
Código da empresaLPCN
Data de listagemMar 21, 2014
CEODr. Mahesh V. Patel, Ph.D.
Executivos da empresa
Nome
Nome/Posição
Posição
Ações detidas
Variação
Dr. Mahesh V. Patel, Ph.D.
Dr. Mahesh V. Patel, Ph.D.
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
109.05K
+1.52%
Mr. John W. Higuchi
Mr. John W. Higuchi
Director
Director
40.80K
--
Dr. Nachiappan Chidambaram, Ph.D.
Dr. Nachiappan Chidambaram, Ph.D.
Senior Vice President - Research and Development
Senior Vice President - Research and Development
4.41K
+11.54%
Ms. Krista Fogarty
Ms. Krista Fogarty
Principal Accounting Officer, Corporate Controller
Principal Accounting Officer, Corporate Controller
1.07K
+44.84%
Dr. Richard Dana Ono, Ph.D.
Dr. Richard Dana Ono, Ph.D.
Independent Director
Independent Director
831.00
--
Mr. Jeffrey A. (Jeff) Fink
Mr. Jeffrey A. (Jeff) Fink
Independent Director
Independent Director
386.00
--
Dr. Jill M. Jene, Ph.D.
Dr. Jill M. Jene, Ph.D.
Independent Director
Independent Director
--
--
Mr. Spyros Papapetropoulos, M.D., Ph.D.
Mr. Spyros Papapetropoulos, M.D., Ph.D.
Lead Independent Chairman of the Board
Lead Independent Chairman of the Board
--
--
Nome
Nome/Posição
Posição
Ações detidas
Variação
Dr. Mahesh V. Patel, Ph.D.
Dr. Mahesh V. Patel, Ph.D.
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
109.05K
+1.52%
Mr. John W. Higuchi
Mr. John W. Higuchi
Director
Director
40.80K
--
Dr. Nachiappan Chidambaram, Ph.D.
Dr. Nachiappan Chidambaram, Ph.D.
Senior Vice President - Research and Development
Senior Vice President - Research and Development
4.41K
+11.54%
Ms. Krista Fogarty
Ms. Krista Fogarty
Principal Accounting Officer, Corporate Controller
Principal Accounting Officer, Corporate Controller
1.07K
+44.84%
Dr. Richard Dana Ono, Ph.D.
Dr. Richard Dana Ono, Ph.D.
Independent Director
Independent Director
831.00
--
Mr. Jeffrey A. (Jeff) Fink
Mr. Jeffrey A. (Jeff) Fink
Independent Director
Independent Director
386.00
--
Detalhamento da receita
Sem dados
Sem dados
Por Empresa
Por Região
Sem dados
Distribuição de ações
Atualizado em: sex, 16 de mai
Atualizado em: sex, 16 de mai
Investidores
Tipos de investidores
Investidores
Investidores
Proporção
The Vanguard Group, Inc.
4.23%
Patel (Mahesh V)
2.04%
BlackRock Institutional Trust Company, N.A.
1.67%
Geode Capital Management, L.L.C.
1.10%
Higuchi (John W)
0.76%
Other
90.20%
Investidores
Investidores
Proporção
The Vanguard Group, Inc.
4.23%
Patel (Mahesh V)
2.04%
BlackRock Institutional Trust Company, N.A.
1.67%
Geode Capital Management, L.L.C.
1.10%
Higuchi (John W)
0.76%
Other
90.20%
Tipos de investidores
Investidores
Proporção
Investment Advisor
6.79%
Individual Investor
2.95%
Investment Advisor/Hedge Fund
2.16%
Hedge Fund
0.72%
Research Firm
0.05%
Other
87.32%
Participação acionária institucional
Atualizado em: ter, 1 de jul
Atualizado em: ter, 1 de jul
Período do relatório
N.º de instituições
Ações detidas
Proporção
Variação
2025Q2
44
678.23K
12.68%
-42.35K
2025Q1
65
678.55K
12.68%
-110.89K
2024Q4
72
645.33K
12.07%
-219.30K
2024Q3
75
703.77K
13.16%
-136.61K
2024Q2
79
690.86K
12.92%
-132.01K
2024Q1
82
639.82K
12.02%
-214.82K
2023Q4
86
649.80K
12.29%
-222.39K
2023Q3
91
667.07K
12.61%
-176.35K
2023Q2
93
641.50K
12.32%
-239.33K
2023Q1
97
745.08K
14.31%
-142.00K
Ver Mais
Atividade dos acionistas
Nome
Ações detidas
Proporção
Variação
Var. %
Data
The Vanguard Group, Inc.
226.28K
4.23%
+4.82K
+2.18%
Mar 31, 2025
Patel (Mahesh V)
109.05K
2.04%
+1.63K
+1.52%
Mar 31, 2025
BlackRock Institutional Trust Company, N.A.
89.27K
1.67%
--
--
Mar 31, 2025
Geode Capital Management, L.L.C.
58.83K
1.1%
+1.37K
+2.38%
Mar 31, 2025
Higuchi (John W)
40.80K
0.76%
--
--
Mar 31, 2025
Susquehanna International Group, LLP
38.98K
0.73%
+13.97K
+55.89%
Mar 31, 2025
Renaissance Technologies LLC
37.51K
0.7%
+1.48K
+4.10%
Mar 31, 2025
Dimensional Fund Advisors, L.P.
24.93K
0.47%
+4.42K
+21.54%
Mar 31, 2025
State Street Global Advisors (US)
18.63K
0.35%
--
--
Mar 31, 2025
Northern Trust Investments, Inc.
13.16K
0.25%
--
--
Mar 31, 2025
Ver Mais
ETFs Relacionados
Atualizado em: sáb, 2 de ago
Atualizado em: sáb, 2 de ago
Nome
Proporção
iShares Core S&P Total U.S. Stock Market ETF
0%
DFA Dimensional US Sustainability Core 1 ETF
0%
Dimensional US Core Equity 1 ETF
0%
iShares Core S&P Total U.S. Stock Market ETF
Proporção0%
DFA Dimensional US Sustainability Core 1 ETF
Proporção0%
Dimensional US Core Equity 1 ETF
Proporção0%
Dividendo
Um total de
0.00
USD foi distribuído em dividendos nos últimos 5 anos.
Data
Dividendo
Data de registro
Data de pagamento
Data ex-dividendo
Sem dados
Desdobramento de ações
Data
Tipo
Proporção
May 11, 2023
Merger
17<1
May 11, 2023
Merger
17<1
May 11, 2023
Merger
17<1
May 11, 2023
Merger
17<1
Data
Tipo
Proporção
May 11, 2023
Merger
17<1
May 11, 2023
Merger
17<1
May 11, 2023
Merger
17<1
May 11, 2023
Merger
17<1
